Skip to content
COVID-19 Rapid Antigen and Antibody Tests - Saliva, Nasal and Nasopharyngeal
COVID-19 Rapid Antigen and Antibody Tests - Saliva, Nasal and Nasopharyngeal

LRRK2 Kinase Enzyme System

by Promega
€455
Size

Recombinant human LRRK2 (968-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. LRRK2 or leucine-rich repeat kinase is a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains (1). LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Downregulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 (2). ADP-Glo Kinase Assay is a luminescent kinase assay that measures ADP formed from a kinase reaction; ADP is converted into ATP, which is a substrate in a reaction catalyzed by Ultra-Glo Luciferase that produces light. The luminescent signal positively correlates with ADP amount and kinase activity. The assay is well suited for measuring the effects chemical compounds have on the activity of a broad range of purified kinases, making it ideal for both primary screening as well as kinase selectivity profiling. The ADP-Glo Kinase Assay can be used to monitor the activity of virtually any ADP-generating enzyme (e.g., kinase or ATPase) using up to 1mM ATP. Kinase Enzyme System contains: Kinase: LRRK2, 10ug (Human, recombinant; amino acids 968-end). MW: ~210kDa. Substrate: LRRKtide (RLGRDKYKTLRQIRQ). Other: Reaction Buffer, DTT. LRRK2 NCBI Database Entry: www.ncbi.nlm.nih.gov/gene/120892/. Visit www.promega.com/kinase/ to see all Kinase Enzyme Systems.